The purpose of this double-blind, randomised trial with a 4-week placebo run-in period followed by an active treatment period using either spirapril 3 mg or 6 mg once a day was to clarify the existence of hypotensive episodes in elderly hypertensive patients treated by an ACE-inhibitor. 
Introduction
Hypertension, apart from being a risk factor for coronary artery disease and stroke, causes adaptive cerebral vascular changes, leading to a shift of the lower limit of autoregulation towards higher pressure with an impaired tolerance to pressure decrease. 1 In young and middle-aged effectively treated hypertensive patients, cerebral blood flow autoregulation may or may not be readapted towards normal. 1 In elderly hypertensive patients non-reversible vascular structural changes would be expected to prevail. Further, atherosclerotic narrowing of the larger cerebral arteries may contribute to impairment of autoregulation by exhausting autoregulatory arteriolar dilatation. In fact Kario et al 2 have shown in their study that the extent of silent cerebrovascular damage was more severe in extreme dippers (nocturnal systolic blood pressure (SBP) fall 21-25%, nocturnal lowest SBP 100-116 mm Hg) compared to dippers (nocturnal SBP fall 13-15%, nocturnal lowest SBP 116-122 mm Hg).
In hypertensive patients the occurrence of cardiac ischaemic episodes could be influenced either by high BP levels, through an increase of myocardial oxygen demand, or by low BP values, through a reduction of coronary perfusion due to an upward shift of the lower limit of coronary autoregulation in the subendocardium. [3] [4] [5] Pierdomenico et al 6 found nocturnal ischaemia significantly more frequently in non-dippers than in dippers and overdippers among untreated hypertensive patients with coronary artery disease. Drug therapy significantly reduced nocturnal ischaemia in non-dippers, had no significant effect in dippers and significantly increased night time ischaemia in overdippers. During treatment, night time ischaemia was significantly more frequent in overdippers than in dippers and nondippers.
Besides the risk of lowering BP too much in elderly people, there is also the risk of over-diagnosing hypertension. 7 The white-coat effect has been shown to correlate positively with the age of the patient. 8 In the study by Kario et al 2 the frequency of silent cerebrovascular damage in the patients with sustained hypertension was greater than that in the patients with white coat hypertension.
This study is a part of a Finnish-Swedish efficacy and safety study of spirapril, an ACE-inhibitor, in elderly hypertensive patients. In this part of the study 24-h ambulatory BP measurement was performed on the Swedish participants of the study to clarify the 24-h BP profile of spirapril, especially its nocturnal antihypertensive effects, in elderly hypertensive patients.
Subjects and methods

Study design
The patients were randomised in a double-blind fashion to spirapril either 3 or 6 mg for 6 weeks after a 4-week single-blind placebo wash-out period. The dose remained stable during the period of active medication and was taken once daily before breakfast.
Subjects
Twenty male and 20 female hypertensive patients with office diastolic BP (DBP) 100-114 mm Hg and SBP р200 mm Hg aged 60-76 years were recruited. Patients with a myocardial infarction within the previous 6 months, severe or unstable angina pectoris, congestive heart failure, non-controlled diabetes mellitus, renal artery disease or arrhythmias were not included.
Eighteen patients, seven men and 11 women, were randomised to the 3 mg dose, and 22 patients, 13 men and nine women, to the 6 mg dose. Baseline characteristics of the patients are given in Table 1 . The patients did not have either coronary heart disease or cerebral artery disease. Other antihypertensive agents, long-acting nitrates, beta-adrenergic blocking agents, calcium-channel blocking agents, diuretics, MAO-inhibitors, tricyclic antidepressants, tranquilizers, lipid-lowering agents and potassium supplements were prohibited. 
Procedures
Heart rate and BP were registered on three occasions during the 4-week placebo phase. Patients entered the active treatment phase if office DBP was 100-114 mm Hg and SBP р200 mm Hg. BP was measured in the sitting position on the right arm in the morning after a 10-min rest, before the intake of placebo or active drug. The mean value of two measurements was used. Ambulatory BP measurement was performed at the end of the placebo period and at 5 weeks of spirapril treatment. For ambulatory BP measurement, the Accutracker II (version 30/23, Suntech Medical Instruments, Raleigh, NC, USA) 9 was used. The BP cuff was placed on the left upper arm. The quality of the ambulatory BP measurement was checked by simultaneous auscultatory BP by one of the authors (EBÅ ). The BP was recorded approximately every 20 min (randomly distributed by the device within the 15-25 min range). The device automatically repeated the measurement if any of the following were recorded: SBP Ͼ220 mm Hg, SBP Ͻ80 mm Hg, change of SBP Ͼ50 mm Hg between two measurements, DBP Ͼ130 mm Hg, DBP Ͻ40 mm Hg, change of DBP Ͼ40 mm Hg, pulse pressure Ͻ20 mm Hg or Ͼ110 mm Hg, or pulse pressure change of Ͼ40 mm Hg. No values were censored except for the value preceding a repeat measurement. Repeat values outside these limits were not excluded from the statistical analyses in order not to miss true values at the extremes.
According to the study protocol, patients were classified as responders if the office DBP was р90 mm Hg or decreased by у10 mm Hg during the active treatment phase.
According to the ambulatory BP measurement the patients were classified as hypertensives if either their average daytime SBP was Ͼ140 mm Hg or average night time SBP Ͼ120 mm Hg or average daytime DBP Ͼ90 mm Hg or average night time DBP Ͼ80 mm Hg (the recommendations of the University of Connecticut Group). 10 Patients who fulfilled the office criteria for inclusion, but had normal ambulatory BP measurement curves, were classified as white-coat hypertensives.
The definition of a low BP in this study was MAP Ͻ50 mm Hg (critically low), corresponding to the lower limit of cerebral autoregulation in healthy persons; and MAP Ͻ70 mm Hg (low), representing the lower limit of cerebral autoregulation in hypertensive patients. 1, 11 The MAP for each measurement was automatically calculated by the Accutracker II equipment.
Safety
Adverse events were checked on four occasions evenly spread throughout the study period. Any change in the patient's condition, even a common cold or shoulder pain, was noted as an adverse event, irrespective of whether a casual relationship to drug therapy was plausible or not.
Statistical analyses
The circadian BP curves are smoothed by applying the three-point moving medians to them (in each place the middle one in size order of the three consecutive measurements is taken). The advantage of the moving median is the removing of all large single deviations.
Proportions were compared with the Fisher's exact, the Chi-square and the Mc'Nemar tests, and continuous variables by two-tailed t-test and ANOVA.
The aim was to recruit 40 patients assuming a statistical power of at least 80%.
Results
In total, 6535 ambulatory BP measurements were registered, of which 954 (17.1%) were repeats which almost equals that found (16%) in the validation study. 8 The number of uncensored readings averaged 68.6 (range 47-76)/ambulatory measurement.
Effects on 24-h ambulatory BP
The mean 24-h daytime SBP was during the placebo period 161. gradually declined until 1 to 2 am, when it had nearly disappeared ( Figure 1) . No second peak of treatment effect, during sleeping hours, was found. The smoothed MAP curves revealed a sharp decline in MAP, from 110 to 95 mm Hg, between 9 and 12 pm (Figure 2 ). This decline seemed to be as rapid and large in the placebo period as in the period of active therapy.
Patients responding to therapy
Eight (44%) of the patients in the 3 mg spirapril group and 12 (55%) in the 6 mg group reached the treatment goal, ie office DBP р90 mm Hg or a fall in DBP у10 mm Hg (P = NS between the groups). Among the office responders, the frequency of MAP Ͻ70 mm Hg was 65%, compared with 25% among non-responders (P Ͻ 0.05). The response rate was lower according to the 24-h ABPM (10) (11% in the 3 mg group and 32% in the 6 mg group, P = 0.12). 
Pattern of critically low blood pressures
No episodes of MAP Ͻ50 mm Hg were seen during the placebo phase, instead 11 (0.4% of measurements, P Ͻ 0.01 compared to placebo) episodes were observed in one patient in the 3 mg spirapril group and three patients in the 6 mg spirapril group (P Ͻ 0.01 between the two groups) ( Table 2) . MAP was Ͻ70 mm Hg in 1.9% of the measurements (12 patients) during the placebo phase and in 4.2% of the measurements during the treatment phase (18 patients) (P Ͻ 0.001) ( Table 2) . Twelve (67%) of those 18 patients had episodes of two or more successive low MAPs. The number of episodes of MAP Ͻ70 mm Hg was higher in the spirapril 6 mg group than in the 3 mg group, both during the placebo period and during the period of active therapy (P Ͻ 0.0001).
Forty (23.4%) of 171 MAPs below 70 mm Hg were repeat values, ie they were registered by an automatic repeat measurement. Such repeats followed extreme values registered at regular time intervals.
The diurnal distributions of MAP Ͻ70 mm Hg during the placebo and the active treatment periods are shown in Figure 3 . In the placebo period low MAPs were almost exclusively observed during night time (11 pm to 6 am). During active treatment, MAP values Ͻ70 mm Hg were also seen during daytime (11 am to 5 pm). The probability of MAP Ͻ70 mm Hg increased during night time, from 5% in the placebo period to 10% during active therapy. Concerning the critically low values (MAP Ͻ50 mm Hg), four of the 11 episodes occurred during the early sleeping hours (11 pm to 1 am), while the remaining seven episodes were evenly distributed (7 am to 5 pm).
The pulse pressure was significantly higher during the placebo period, according to office measurements, in patients with MAP Ͻ70 mm Hg than in other patients 62.6 (12.5 s.d.) mm Hg vs 58.3 (10.9) mm Hg, (P Ͻ 0.01). During the placebo period office SBP did not differ between the patients with MAP Ͻ70 mm Hg and those with MAP у70 mm Hg (157.2 (13.0) mm Hg vs 157.7 (11.6) mm Hg). Instead DBP was significantly lower in the hypotensive patients than in the nonhypotensive patients (94.6 (6.5) mm Hg vs 99.4 (6.5) mm Hg, P Ͻ 0.001). Heart rate was a little higher (81.3 (9.6) bpm and 78.1 (12.9) bpm, respectively, P Ͻ 0.05).
White-coat effect
Two patients in both spirapril groups were normotensive in the placebo phase according to the ABPM (criteria of the University of Connecticut Group). 10 Three of them had MAP values Ͻ70 mm Hg during active treatment. Twenty-one of the 36 true hypertensive patients did not have critically low BP during spirapril treatment.
Clinical safety
Adverse events were seen in 14 (78%) of the patients with MAP Ͻ70 mm Hg and in 13 (59%) of the other patients (NS). The number of adverse events (some of which occurred in the same patient) was 14 in the group with low BP and 18 in the other group. The adverse events were rather well tolerated, and no patient had to discontinue medication because of them.
Discussion
According to our study antihypertensive medication with the ACE-inhibitor spirapril significantly increased hypotensive episodes in these elderly hypertensive patients.
The increasing amount of hypotensive episodes during antihypertensive treatment seen in our study may expose the elderly patients to the hazard of a critical fall in cerebral blood flow (CBF) because hypertension leads to a shift of the lower limit of cerebral autoregulation towards higher pressure with an impaired tolerance to pressure decrease. 1 This functional haemodynamic adaptation is probably caused by structural hypertensive vascular changes. 12 In middle-aged effectively treated hypertensive patients CBF autoregulation may be readapted towards normal. 1 However, in elderly hypertensive patients non-reversible hypertensive vascular structural changes would be expected to prevail and hence functional vascular readaptation is not likely to take place when BP is lowered. Fortunately the brain can extract additional oxygen when perfusion is reduced.
The effect of spirapril on cerebral autoregulation has not been studied. Captopril given intravenously has shortened the autoregulatory plateau shifting both the lower and the upper limit of autoregulation towards lower BP in acute studies in rats. 13 During chronic treatment the shift of the lower limit of autoregulation towards lower BP is retained, while the less desirable shift of the upper limit is not present.
14 Also in heart failure patients captopril similarly maintained a normal CBF as very low BP. 15, 16 The effect of spirapril is probably comparable to the effect of captopril because it has been suggested that the ACE-inhibitors exert their effect by inhibiting angiotensin II-dependent tone in the larger cerebral resistance vessels. 17 Thus it is possible that the change towards more hypotensive episodes seen in our study is alleviated by the use of the ACE-inhibitor treatment. However, we did not measure in our study the ischaemia of target organs which leads only to speculation of the effect of the hypotensive episodes seen.
All the investigations concerning the effects of antihypertensive medication on CBF have been performed during daytime, not during sleeping hours, when most of the hypotensive episodes in this study were found. Therefore, little or nothing is known about regional CBF in any clinical situation other than that of the awake and supine patient.
In the study of Pierdomenico et al 6 myocardial ischaemia increased during the night time in the treated overdippers, and the change was associated with the lowest BP values. Thus it seems that druginduced excessive BP lowering leads to hypoperfusion in the presence of significant coronary artery stenoses. Moreover, in hypertensive patients also coronary autoregulation in the subendocardium is shifted toward higher pressure, probably owing to Journal of Human Hypertension left ventricular hypertrophy and functional and structural alterations in the small coronary vessels. 3, 5, 18, 19 The relationship between CBF and MAP has been established by invasive BP measurements. 1, 20 In general, the non-invasive approach tends, when compared with the invasive approach, to underestimate SBP and overestimate DBP, 21 but the differences are small. The accuracy of non-invasive ABPM readings in daily life is rather poor, 22 but the readings of an Accutracker II have been shown not to deviate more than 4 mm Hg from intra-arterial readings, both at rest and during exercise. 23 Therefore, it seems reasonable to assume that our low MAP values data indicate real values close to the lower limit of cerebral autoregulation.
In ABPM there is a risk of missing important information about readings on the border of physiologically acceptable ranges. The automatic data censoring introduced to reduce movement artifacts may induce bias. It tends to reject low-level outliers and night-time readings to a greater extent than highlevel outliers. 22 The device used in this study (Accutracker II) does not reject readings automatically but repeats the measurement. We censored only primary extreme readings to avoid artifacts, but no repeat readings. It seems improbable that low MAP values seen were only caused by technical reasons.
The hypotensive episodes were more common among the patients with lower achieved BP level. Thus it might be rational not to set the goal of BP too low in elderly patients although the HOTstudy 24 and the former studies in the elderly 25 have not shown increased cardiovascular risk even in quite low DBP levels.
In our study the treatment of white coat patients led to frequent hypotensive episodes which suggests that white coat patients should be picked up to avoid unnecessary antihypertensive medications.
The clinical importance of our observations with regard to the risk of developing hypotensive tissue damage is unclear because we did not measure target organ ischaemia. In patients with glaucoma, a correlation between progressive visual field deterioration and nocturnal hypotension has been observed. 26 In healthy humans, responses of CBF to sudden changes in arterial BP have been found to be extremely rapid. Also, the brain can maintain an unchanged metabolism by extracting more oxygen from the blood, when CBF falls. 27, 28 However, these compensatory mechanisms are assumed to be weakened in the elderly. 2 The higher pulse pressure seen in patients with more hypotensive episodes was caused by lower DBP, and may indicate stiffer vessel walls and more widespread changes in cerebral resistance vessels. 29 According to our results the question of critically low BP during antihypertensive medication deserves attention especially in the elderly patients. We propose that ABPM should, at least in some patients, be included in the decision making of starting antihypertensive medication and in the follow-up of antihypertensive treatment in the elderly, and that automatic censoring of data should be abolished.
